Www.pbm.va.gov
The ACCF/AHA UA/NSTEMI and STEMI guidelines do not prefer one agent over another. The Committee recognizes that there may be benefits with the newer agents compared to clopidogrel that have been shown in one single, large clinical trial each for both prasugrel and ticagrelor. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.